News
FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...
In light of recent patient deaths, the FDA has also revoked its platform designation for Sarepta’s AAVrh74 technology. The ...
Sarepta Therapeutics faces challenges as the FDA halts gene therapy trials for LGMD and revokes AAVrh74 platform designation.
Separately, the FDA on Friday informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, that is approved to treat a different type of muscular dystrophy and was ...
Stock futures ticked higher Monday premarket, kicking off a busy week packed with big tech earnings. Here are some of Monday's biggest stock movers: Biggest stock gainers Block (NYSE:XYZ) +9% – Shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results